This page includes Regulatory news filings supplied by issuers listed on the BSX. Please note the BSX is not responsible for the content, accuracy or completeness of announcements filed by issuers and disclaims all liability for any loss arising from reliance on information contained within issuer announcements.
Jazz Pharmaceuticals PLC Announces Full Year & Fourth Quarter 2017 Financial Results
Hamilton, Bermuda – 5 March 2018 – In a filing with the Bermuda Stock Exchange (the “BSX”), the parent of BSX listed Jazz Investments I Limited, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced full year and fourth quarter 2017 financial results.
• Total revenues of $1.6 billion in 2017
• GAAP EPS of $7.96 per share in 2017
• Adjusted non-GAAP EPS of $11.04 per share in 2017
• Solriamfetol new drug application submitted in December 2017
To view the full filing please visit:
www.bsx.com/CompanyDocuments/1099938868/4Q17%20Press%20Release.pdf